Mandom Indonesia (TCID) Stock 2026: Financial Recovery, Valuation, Risks, and What U.S. Investors Should Know
Mandom Indonesia (TCID) Stock 2026: Financial Recovery, Valuation, Risks, and What U.S. Investors Should Know
 |
| PT Mandom Indonesia Tbk (IDX: TCID) |
Worldreview1989 - PT Mandom Indonesia Tbk (IDX: TCID) is a consumer-goods company that may look unfamiliar to most U.S. investors, but its business model is relatively easy to understand: cosmetics, personal care, fragrances, hair care, and related products.
The company owns or markets established brands such as GATSBY, PIXY, PUCELLE, MIRATONE, and LUCIDO-L, while also exporting products to markets across Asia and the Middle East.
For investors evaluating TCID in 2026, however, the story is no longer simply about whether Mandom can survive a period of losses.
The more important question is:
Can Mandom Indonesia turn its 2025 financial recovery into sustainable, high-quality earnings?
The answer is promising—but not yet proven.
This updated analysis replaces the earlier view that focused heavily on negative earnings. Mandom returned to profitability in 2025, and its balance sheet remains relatively conservative. However, its very low earnings base means that investors should not automatically interpret a low price-to-book ratio as proof that the stock is cheap.
Mandom Indonesia at a Glance
| Metric | Latest figure |
|---|---|
| Stock | IDX: TCID |
| Shares outstanding | 402.13 million |
| FY2025 net sales | Rp2.147 trillion |
| FY2025 gross profit | Rp551.8 billion |
| FY2025 operating profit/loss | Rp8.9 billion operating loss |
| FY2025 net income | Rp15.3 billion |
| Q1 2026 net sales | Rp513.7 billion |
| Q1 2026 net income | Rp26.2 billion |
| Q1 2026 operating profit | Rp25.7 billion |
| Q1 2026 cash | Rp666.4 billion |
| Q1 2026 total liabilities | Rp456.2 billion |
| Q1 2026 shareholders' equity | Rp1.834 trillion |
| Latest verified market price used | Rp2,780 |
| Approx. market capitalization | Rp1.12 trillion |
| Approx. market cap in USD | ~$62.7 million* |
*USD conversion uses approximately Rp17,828 per U.S. dollar, close to the August 14, 2026 market reference. Currency conversion is only illustrative because exchange rates fluctuate.
What Does Mandom Indonesia Actually Do?
Mandom Indonesia was established in 1969 and began commercial production in 1971. Its core business is the manufacture and sale of cosmetics and personal-care products.
The company's main product categories include:
Hair care
Skin care and makeup
Fragrances
Other personal-care products
Its major brands include GATSBY, PIXY, PUCELLE, MIRATONE, and LUCIDO-L. Mandom also exports to countries including the United Arab Emirates, Japan, India, Malaysia, Vietnam, Thailand, and other markets.
For an American investor, the important point is that TCID is not a pure domestic Indonesian company. International sales remain an important part of the business.
However, domestic Indonesia is still the company's largest market.
The Biggest Change: Mandom Returned to Profitability
The previous version of this analysis emphasized Mandom's losses.
That conclusion is now outdated.
Mandom reported Rp2.147 trillion of net sales in 2025, up approximately 15.4% from Rp1.859 trillion in 2024.
More importantly, net income improved from a Rp124.7 billion loss in 2024 to a Rp15.3 billion profit in 2025.
This represents a substantial turnaround.
FY2024 vs. FY2025
| Metric | FY2024 | FY2025 | Change |
|---|---|---|---|
| Net sales | Rp1.859T | Rp2.147T | +15.4% |
| Gross profit | Rp241.8B | Rp551.8B | +128.2% |
| Operating result | -Rp198.4B | -Rp8.9B | Major improvement |
| Net income | -Rp124.7B | Rp15.3B | Turnaround |
| Gross margin | ~13.0% | ~25.7% | Significant improvement |
The improvement in gross margin is particularly important.
Mandom reduced its cost-of-goods-sold ratio from approximately 87.0% in 2024 to 74.3% in 2025. This was attributed to improvements in production systems, raw-material cost monitoring, and resource management.
That is arguably more important than the headline revenue growth.
A consumer-products company can grow revenue while destroying shareholder value if gross margins deteriorate. Mandom did the opposite in 2025: sales increased while gross profitability improved dramatically.
Domestic Sales Were the Main Growth Engine
One of the strongest elements of the 2025 recovery was domestic Indonesia.
Domestic sales increased approximately 30.9%, from Rp1.10 trillion to Rp1.44 trillion.
Meanwhile, export sales declined approximately 6.4%, from Rp760.18 billion to Rp711.28 billion. Management attributed part of the export weakness to slower economic conditions in several Southeast Asian markets.
This creates an interesting investment profile.
Positive
Indonesia is the company's largest market, so stronger domestic consumer demand can materially improve earnings.
Negative
Export weakness means the international growth story is not currently as strong as the domestic recovery.
For U.S. investors, this distinction matters because TCID should not be viewed as a rapidly expanding global beauty company comparable to a multinational U.S. cosmetics business.
It is better understood as an Indonesian consumer-products recovery story with regional exports.
Q1 2026: Still Profitable, But Revenue Declined
The first-quarter 2026 results provide an important reality check.
Mandom reported:
Net sales: Rp513.7 billion
Gross profit: Rp145.5 billion
Operating profit: Rp25.7 billion
Net income: Rp26.2 billion
However, Q1 revenue was down from Rp551.2 billion in Q1 2025, a decline of approximately 6.8%.
Net income also declined from Rp30.2 billion to Rp26.2 billion, approximately 13.4% lower year over year.
So the 2026 picture is mixed.
The good news is that profitability remained positive.
The concern is that revenue momentum weakened.
This is exactly why investors should avoid extrapolating Q1 earnings mechanically across the entire year.
Q1 2026 Margins Look Much Better
Although revenue declined, Mandom still generated a healthy improvement in operating profitability compared with its recent history.
Q1 2026
Gross margin: approximately 28.3%
Operating margin: approximately 5.0%
Net margin: approximately 5.1%
This compares with approximately:
28.5% gross margin in Q1 2025
5.8% operating margin in Q1 2025
5.5% net margin in Q1 2025
The numbers show that Mandom has not returned to the extraordinary profitability levels of a high-margin beauty company.
But it has moved far away from the severe operating losses seen in 2024.
That is an important distinction.
Balance Sheet: One of TCID's Strongest Arguments
Mandom's balance sheet is arguably more attractive than its income statement.
At March 31, 2026, the company reported:
Cash and cash equivalents: Rp666.4 billion
Total assets: Rp2.29 trillion
Total liabilities: Rp456.2 billion
Total equity: Rp1.834 trillion
This produces a current ratio of roughly 6.6x.
That is a substantial liquidity cushion.
The company also had only modest lease liabilities and did not appear to depend heavily on conventional financial debt.
For a value investor, this is important because the balance sheet reduces financial distress risk.
But investors should not confuse a strong balance sheet with a strong business.
A company can have significant cash and still generate mediocre returns on capital.
Inventory Is an Important Risk
There is one balance-sheet item that deserves special attention: inventory.
At December 31, 2025, Mandom reported inventory of approximately Rp602.1 billion, representing about 26% of total assets.
The independent auditor identified inventory valuation as a key audit matter, particularly because cosmetics and personal-care products can become obsolete and their net realizable value can change.
This is a meaningful risk.
Beauty and personal-care products are not necessarily like industrial machinery that can sit on a balance sheet for years.
Consumer preferences change.
Packaging changes.
Product formulations change.
New products replace older products.
Therefore, investors should monitor:
Inventory growth versus sales growth
Inventory write-downs
Gross margin
Product launches
Promotional spending
Cash conversion
A large inventory balance is not automatically bad, but it needs to generate sales efficiently.
Financial Quality: The Recovery Is Real, but Still Early
A useful way to analyze TCID is to separate financial recovery from earnings quality.
Financial recovery: Strong
Mandom moved from a Rp124.7 billion net loss in 2024 to a Rp15.3 billion profit in 2025.
Gross-margin recovery: Very strong
Gross profit increased 128.2% in 2025.
Operating recovery: Almost complete
The operating loss narrowed from Rp198.4 billion to just Rp8.9 billion.
Sustainable profitability: Not yet proven
The company's full-year net profit was only Rp15.3 billion.
That is a very small profit relative to its Rp2.15 trillion revenue base.
Therefore, TCID is still in the proof-of-sustainability stage.
Valuation: TCID Looks Cheap on Book Value but Expensive on Earnings
This is where the investment thesis becomes more complicated.
Using a reference price of approximately Rp2,780 per share, and 402.13 million shares outstanding, TCID's implied market capitalization is approximately Rp1.12 trillion. The most recent historical quote I could verify was Rp2,780 on July 27, 2026; investors should verify the live IDX quote before trading.
Based on Q1 2026 shareholders' equity of approximately Rp1.834 trillion:
Book value per share
Approximately:
Rp1.834 trillion ÷ 402.13 million shares = Rp4,561 per share
At Rp2,780, that implies:
Price-to-book ratio ≈ 0.61x
That looks inexpensive.
But earnings tell a very different story.
FY2025 EPS was only around Rp38 per share.
At Rp2,780:
P/E ≈ 73x
That is expensive if FY2025 earnings are representative of normalized earnings.
Even using a simple trailing calculation incorporating Q1 2026 and removing Q1 2025:
FY2025 net income + Q1 2026 net income − Q1 2025 net income
≈ Rp15.3B + Rp26.2B − Rp30.2B
≈ Rp11.2 billion trailing earnings
That produces an approximate trailing EPS of only Rp28, implying a P/E close to 100x.
This is the key issue.
TCID may be cheap relative to book value while simultaneously being expensive relative to current earnings.
Investors should therefore avoid describing TCID simply as an "undervalued stock."
It is more accurate to call it a balance-sheet value/recovery stock whose valuation depends heavily on future earnings improvement.
Why the Low P/B Ratio May Be Misleading
A 0.6x price-to-book ratio sounds attractive.
But book value is not the same thing as earning power.
If a company owns substantial assets but produces only modest returns on those assets, the market can rationally value it below book.
Mandom's 2025 return on equity was still low because the company generated only a small net profit against more than Rp1.7 trillion of equity.
Therefore, the investment thesis requires a second stage:
Mandom must convert its strong balance sheet into consistently higher earnings.
That means investors should watch whether operating margins can remain above 4–5% and eventually move higher.
Mandom's Brands Are a Competitive Advantage
Mandom's brand portfolio provides some protection against pure commodity competition.
GATSBY is particularly important.
The company describes GATSBY as a leading men's hairstyling brand in Indonesia, with products spanning wax, gel, pomade, clay, fragrance, body care, and face care.
PIXY is another important brand, particularly in women's cosmetics and skin care. The company has also emphasized PIXY's rebranding and product innovation as part of its recovery strategy.
These brands give Mandom something that a generic manufacturer does not have:
consumer recognition.
However, brand recognition does not eliminate competition.
The beauty market is extremely dynamic, particularly among younger consumers.
Marketing Spending Is a Double-Edged Sword
Mandom increased operating expenses by approximately 27.4% in 2025, partly because of more active marketing and promotional activities.
That helped support the company's recovery strategy, but it also means investors need to distinguish between:
productive brand investment, and
spending that merely protects revenue.
A successful marketing campaign should eventually generate:
higher sales → higher gross profit → higher operating income → higher free cash flow.
If marketing expenses rise faster than gross profit for several years, shareholders may not benefit even when revenue grows.
Export Exposure Creates Both Opportunity and Risk
Mandom sells into markets including the UAE, Japan, Malaysia, Thailand, Vietnam, India, and other countries.
According to the 2025 financial statements, Indonesia accounted for approximately 67% of sales, while the UAE represented about 11% and Japan about 7%.
This gives Mandom some geographical diversification.
But it also creates exposure to:
Foreign exchange movements
Regional economic cycles
Consumer demand
Shipping costs
Local regulations
Competitive pricing
For a U.S. investor, this adds another layer of risk because the investor is effectively exposed to both TCID's operating performance and the Indonesian rupiah.
Royalty Payments to Mandom Corporation Matter
Mandom Indonesia has a royalty agreement with Mandom Corporation of Japan for the use of certain brands and technology.
The 2025 audited financial statements show royalty and trademark fees of approximately Rp94.7 billion, equivalent to around 5.94% of cost of goods sold.
The agreement specifies royalty rates ranging from 2% to 6% of relevant net sales.
For investors, this is important because the relationship with the Japanese parent company is both:
A strength
Mandom Indonesia benefits from established technology, brands, and group relationships.
A cost
Royalty payments reduce the economic profit available to shareholders.
Therefore, when evaluating TCID, investors should look at earnings after related-party royalties rather than evaluating gross margins alone.
What Could Make TCID Stock Attractive?
There are several potential catalysts.
1. Sustainable operating profitability
If Mandom can maintain operating margins above 5% and gradually increase them, earnings could grow much faster than revenue.
2. Domestic consumer recovery
Indonesia represents the majority of sales, so continued domestic growth could materially improve earnings.
3. PIXY and GATSBY innovation
Successful product launches could improve revenue without requiring a proportional increase in fixed costs.
4. Better asset utilization
The company has substantial equity and cash. Higher sales and margins could improve ROE.
5. Re-rating from below book value
If profitability becomes sustainable, the market could assign a higher P/B multiple.
What Could Go Wrong?
The risks are equally important.
1. Profitability could remain weak
The biggest risk is that the 2025 turnaround proves temporary.
2. Revenue momentum could weaken
Q1 2026 revenue was already lower year over year.
3. Competition
Cosmetics and personal care have relatively low switching costs.
Consumers can easily move to competing brands.
4. Inventory risk
Inventory represented a significant portion of assets and was specifically highlighted as a key audit matter.
5. Currency risk
U.S. investors face IDR/USD exchange-rate fluctuations in addition to stock-price risk.
6. Liquidity risk
TCID is a relatively small Indonesian listed company. Trading liquidity can be considerably lower than what U.S. investors are accustomed to with NYSE or Nasdaq stocks.
A thinly traded stock can create:
wider bid/ask spreads,
larger price movements from relatively small orders,
difficulty exiting large positions.
This makes position sizing particularly important.
What U.S. Investors Should Know
TCID is an Indonesia Stock Exchange-listed security, not a mainstream NYSE/Nasdaq consumer stock.
That means a U.S. investor needs to consider additional risks:
Currency
Returns in U.S. dollars depend on both the stock price and IDR/USD movements.
Market access
Investors need a brokerage or custody arrangement capable of accessing Indonesian equities.
Liquidity
TCID's trading volume can be significantly lower than major U.S. consumer companies.
Corporate governance
Investors should carefully review Indonesian public disclosures, related-party transactions, ownership structures, and shareholder resolutions.
Tax
Dividend taxation can involve both Indonesian withholding and U.S. tax reporting considerations.
The U.S.-Indonesia tax treaty provides that dividends paid to a beneficial owner resident in the other country may be taxed by both countries, with the source-country tax generally capped at 15% of gross dividends under the treaty's conditions. U.S. investors should consult the current IRS guidance and a qualified tax professional because treaty eligibility, documentation, foreign tax credits, account type, and individual circumstances can change the actual tax outcome.
Bull Case vs. Bear Case
| Bull Case | Bear Case |
|---|---|
| Sales recovery continues | Revenue growth slows |
| Gross margins remain elevated | Input costs rise |
| GATSBY remains strong | Competitors gain market share |
| PIXY rebranding succeeds | Marketing expenses remain high |
| Operating margin reaches 5%+ | Profit remains very small |
| ROE improves substantially | Large equity base generates weak returns |
| Stock re-rates toward book value | Low P/B persists for a reason |
| Export markets recover | Export sales continue declining |
A More Useful Way to Value TCID
Rather than relying on a single P/E ratio, investors should monitor three valuation variables:
1. Price-to-book
At approximately 0.61x, TCID appears inexpensive relative to its book value.
2. Normalized P/E
Current earnings are too low to make the stock look cheap on a conventional P/E basis.
3. Earnings power
This is the most important variable.
If Mandom eventually produces Rp100–Rp150 of sustainable annual EPS, the current price becomes much easier to justify.
For example:
At Rp100 EPS:
Rp2,780 ÷ Rp100 = 27.8x P/E
At Rp150 EPS:
Rp2,780 ÷ Rp150 = 18.5x P/E
At Rp200 EPS:
Rp2,780 ÷ Rp200 = 13.9x P/E
This illustrates why the investment case depends heavily on future profitability rather than current earnings.
My 2026 Investor Assessment
For a U.S. investor, I would categorize TCID as:
Financial strength: 8/10
The balance sheet is conservative, liquidity is strong, and liabilities are relatively modest.
Business quality: 6.5/10
Established brands are a positive, but competition and consumer trends remain challenging.
Growth: 6/10
Domestic sales growth in 2025 was impressive, but Q1 2026 showed weaker revenue momentum and exports declined during 2025.
Profitability: 5.5/10
The turnaround is encouraging, but absolute earnings remain small.
Valuation: 6/10
Cheap on book value, but expensive on current earnings.
Risk: 7/10
Small-cap status, Indonesian market exposure, currency risk, liquidity, competition, and uncertain normalized earnings all matter.
Final Verdict: Is Mandom Indonesia Stock a Buy in 2026?
Mandom Indonesia's investment story has improved materially since the previous analysis.
The company is no longer primarily a turnaround story based on avoiding losses.
It has already achieved a significant portion of the turnaround:
Revenue increased 15.4% in 2025.
Gross profit increased 128.2%.
The 2024 net loss turned into a 2025 net profit.
Q1 2026 remained profitable.
Cash exceeded Rp666 billion.
Equity exceeded Rp1.8 trillion.
Total liabilities remained relatively low.
But investors should not stop the analysis there.
The market is currently assigning a relatively high valuation to the company's small earnings base despite a price below book value.
Therefore, TCID is not an obvious bargain simply because its P/B ratio is below 1x.
The real investment thesis is:
Mandom Indonesia becomes attractive if management can transform the 2025–2026 gross-margin recovery into sustainably higher operating income and ROE.
For a long-term investor, the most important indicators to monitor are:
Annual net sales growth
Gross margin
Operating margin
ROE
Inventory growth
Operating cash flow
Domestic sales
Export sales
Marketing expenses
Sustainable EPS
If operating profit and EPS continue to improve while the stock remains below book value, the risk/reward profile could become considerably more attractive.
If earnings stagnate near current levels, the low P/B ratio alone may not be enough to generate strong shareholder returns.
Bottom line: TCID is best viewed in 2026 as a financial-recovery and asset-value opportunity—not yet a proven high-quality compounder.
U.S. investors should also remember that TCID carries emerging-market, currency, liquidity, and Indonesian regulatory risks that would not normally be present to the same degree in a large U.S.-listed consumer stock.
Investment Disclaimer
This article is for educational and informational purposes only and does not constitute investment, financial, tax, or legal advice. TCID is an Indonesian-listed security and may involve significant liquidity, currency, emerging-market, regulatory, and market risks. Past performance does not guarantee future results. U.S. investors should conduct their own due diligence and consult a qualified financial or tax professional before investing.
Primary Sources and References
PT Mandom Indonesia Tbk — Annual Reports
Mandom Indonesia Annual Report & Investor Relations
PT Mandom Indonesia Tbk — Quarterly Reports
Mandom Indonesia Quarterly Reports
PT Mandom Indonesia Tbk — Investor Relations
Mandom Indonesia Investor Relations
PT Mandom Indonesia Tbk — 2025 Annual Report Summary
Mandom Indonesia 2025 Annual Report Summary
PT Mandom Indonesia Tbk — Audited FY2025 Financial Statements
Audited Mandom Indonesia FY2025 Financial Statements
PT Mandom Indonesia Tbk — Q1 2026 Financial Statements
Mandom Indonesia Q1 2026 Financial Statements
PT Mandom Indonesia Tbk — Company Profile
Mandom Indonesia Company Profile
Indonesia Stock Exchange / IDX disclosures
Indonesia Stock Exchange
U.S. Internal Revenue Service — U.S.-Indonesia Tax Treaty
IRS — Indonesia Tax Treaty Documents
U.S. Internal Revenue Service — U.S.-Indonesia Tax Convention
IRS — U.S.-Indonesia Tax Convention
Bank Indonesia — Official Exchange Rates
Bank Indonesia Exchange Rate Information
About the Author
David Mulyana is the founder and editor of WorldReview1989, an independent publication dedicated to finance, investing, insurance, business, technology, and digital marketing.
He researches and writes in-depth articles that help readers understand complex financial topics through clear explanations, practical insights, and data-driven analysis. His editorial focus includes stock market investing, cryptocurrencies, banking, personal finance, business insurance, real estate, startup strategies, and emerging technology trends.
Every article published on WorldReview1989 is created with a commitment to accuracy, transparency, and reader value. Content is reviewed regularly to reflect the latest market developments, industry updates, and publicly available information from trusted sources.
Editorial Principles
- Accuracy before speed
- Independent and unbiased analysis
- Clear, easy-to-understand explanations
- Information supported by reputable public sources
- Regular updates to maintain content relevance
Areas of Expertise
- Personal Finance
- Investing & Stock Market
- Cryptocurrency & Blockchain
- Insurance
- Banking
- Real Estate
- Business & Entrepreneurship
- Digital Marketing
- Financial Technology (FinTech)
About WorldReview1989
WorldReview1989 provides educational content for readers seeking reliable information about finance, investment opportunities, insurance, business strategies, and technology. The website aims to simplify complex financial concepts and empower readers to make informed decisions.
Disclaimer: The information published on WorldReview1989 is for educational and informational purposes only. It should not be considered financial, legal, tax, or investment advice. Readers should consult qualified professionals before making financial decisions.
David Mulyana writes about stocks, financial markets, investment strategies, insurance and emerging-market opportunities, with a focus on helping readers understand financial data and investment risks
Join Facebook Group
Comments
Post a Comment